Investigational drug · Phase 3
VRT106
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, HCC.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
9
Any phase or sponsor naming "VRT106"
First trial start
2025
Sep 2, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VRT106", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diffuse Midline Glioma, H3 K27M-Mutant
- Diffuse Intrinsic Pontine Glioma
- HCC
- Glioblastoma
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "VRT106" as an intervention, largest first.
- A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCCPivotal-lookingRecruiting
Guangzhou Virotech Pharmaceutical Co., Ltd.Industry
NCT07589244 · 66 participants (planned) · Start May 13, 2026 · Primary completion Dec 31, 2028
Drug: VRT106; VRT106 in combination with camrelizumab and apatinib and 1 more · For: HCC
Sites: Guangzhou, China
Guangzhou Virotech Pharmaceutical Co., Ltd.Industry
NCT07093814 · 42 participants (planned) · Start Sep 2, 2025 · Primary completion Dec 31, 2028
Drug: VRT106 · For: Glioblastoma
Sites: Hefei, China; Beijing, China; Chongqing, China · 11 sites in all
Guangdong Provincial People's HospitalAcademic, hospital or other
NCT07486310 · 30 participants (planned) · Start Mar 1, 2026 · Primary completion Mar 1, 2028
Drug: Doxorubicin (Adriamycin); VRT106 · For: Advanced Gastric Cancer
Sites: Guangzhou, China
Guangzhou Virotech Pharmaceutical Co., Ltd.Industry
NCT06368921 · 30 participants (planned) · Start Jun 19, 2024 · Primary completion Sep 2027
Drug: VRT106 · For: Solid Tumor
Sites: Guangzhou, China; Zhengzhou, China; Jinan, China
Guangdong Provincial People's HospitalAcademic, hospital or other
NCT06758544 · 18 participants (planned) · Start Mar 17, 2025 · Primary completion Sep 30, 2026
Drug: Oncolytic virus VRT106; Chemotherapy · For: Pancreatic Cancer
Sites: Guangzhou, China
Guangzhou Virotech Pharmaceutical Co., Ltd.Industry
NCT06046742 · 12 participants (planned) · Start Jul 10, 2024 · Primary completion Jun 30, 2028
Drug: M1-c6v1 · For: Solid Tumor
Sites: Kashiwa-shi, Japan; Matsuyama, Japan; Kawasaki-shi, Japan
Guangzhou Virotech Pharmaceutical Co., Ltd.Industry
NCT06826313 · 12 participants (planned) · Start Mar 19, 2025 · Primary completion Dec 30, 2028
Drug: VRT106 · For: Solid Tumors
Sites: Guangzhou, China
- A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic CancerNot yet recruiting
Xiangya Hospital of Central South UniversityAcademic, hospital or other
NCT06866977 · 10 participants (planned) · Start Mar 12, 2025 · Primary completion Oct 31, 2025
Drug: Oncolytic virus VRT106; Chemotherapy · For: Pancreatic Cancer
Sites: Changsha, China
Guangzhou Virotech Pharmaceutical Co., Ltd.Industry
NCT07589257 · 10 participants (planned) · Start May 7, 2026 · Primary completion Jun 30, 2028
Drug: VRT106 for injection · For: Diffuse Midline Glioma, H3 K27M-Mutant; Diffuse Intrinsic Pontine Glioma
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.